WO2024136781A1 - Novel formulation for using in the treatment of wounds - Google Patents
Novel formulation for using in the treatment of wounds Download PDFInfo
- Publication number
- WO2024136781A1 WO2024136781A1 PCT/TR2023/050010 TR2023050010W WO2024136781A1 WO 2024136781 A1 WO2024136781 A1 WO 2024136781A1 TR 2023050010 W TR2023050010 W TR 2023050010W WO 2024136781 A1 WO2024136781 A1 WO 2024136781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wounds
- formulation
- treatment
- wound
- surfactant
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 28
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000009472 formulation Methods 0.000 title claims abstract description 24
- 210000000416 exudates and transudate Anatomy 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 6
- 229920002413 Polyhexanide Polymers 0.000 claims description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229940093158 polyhexanide Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
Definitions
- the invention relates to a new formulation that has antiseptic and antibacterial properties and has the effect of breaking down the enzyme contained in the exudate formed in the wounds, to be used in the treatment of wounds.
- Topical applications used for the purpose of treating wounds are usually in the form of solutions or gels.
- formulations containing polynexamethylene biguanide (PHMB) and surfactant are commonly preferred.
- the effectiveness of the existing products is to clean the layers on the wound surface and to provide wound antisepsis, especially in chronic wounds.
- On the wound surface there are remnants of wound exudate, layers of discarded and thickened fibrin, layers of necrotic tissue and cell debris. These layers prepare a suitable environment for pathogenic microbes to infect the wound. Even in the absence of pathogenic microbes, removal of the layers on the wound surface and deep cleaning and disinfection of the wound are extremely important factors in accelerating the healing process.
- PHMB is a suitable compound as a microbicide with good tissue tolerance.
- Wound compositions containing PHMB applied in the form of gels and lotions are known.
- situations arise such as not providing protection satisfactorily, not cleaning the wound from harmful substances, not reducing pain, not having an ingredient that will support the healing process, and not providing moisturizing.
- W02015107183 Al relates to new formulations useful in the topical treatment of skin and oromucosal wounds.
- the formulations disclosed in the document consist of a polyhexamethylene biguanide as an antimicrobial agent, purified water and a triblock copolymer composed of a triblock copolymer, in particular polyethylene oxide and polypropylene oxide, and more particularly a poloxamer, and may be in solution or gel form.
- a triblock copolymer composed of a triblock copolymer, in particular polyethylene oxide and polypropylene oxide, and more particularly a poloxamer, and may be in solution or gel form.
- sodium bicarbonate content and function there is no explanation for the sodium bicarbonate content and function.
- a wound healing product formulated to be used in wound dressing contains polyhexanide, at least one surfactant and hydroxyethyl cellulose.
- the formulation contains polyhexanide, at least one surfactant and hydroxyethyl cellulose.
- cytotoxic antimicrobial active compound that increases wound collagen formation in the application. The absence of such an ingredient indirectly contributes to the healing process of the wound.
- the invention aims to bring a solution for the negative aspects for new formulation for using in the treatment of wounds, stated above, constructed with the inspiration from the current state of art.
- the invention is inspired by current situations and aims to solve the above-mentioned disadvantages.
- the main purpose of the invention is to develop a new formulation for use in the treatment of wounds.
- This formulation unlike the products in the state of the art, comprises sodium bicarbonate and accordingly, it is possible to break down the enzyme contained in the exudate formed in the wounds.
- the invention relates to a new formulation that has antiseptic and antibacterial properties and has the effect of breaking down the enzyme contained in the exudate formed in the wounds, to be used in the treatment of wounds.
- the formulation which is the subject of the invention comprises polyhexamethylene biguanide (PMBH) as an active ingredient (preservative).
- PMBH polyhexamethylene biguanide
- surfactant poloxamer and Cola Lipid C are also included in the formulation.
- Another ingredient in the formulation is sodium bicarbonate, which acts as an enzyme-dissolving aid.
- PHMB, poloxamer and Cola Lipid C provide antiseptic and antibacterial effects to the formulation.
- sodium bicarbonate in the formulation also breaks down the enzyme contained in the exudate and brings a new feature to the product.
- the formulation comprises 0.01-10% polyhexamethylene biguanide (PMBH), 0.01-10% poloxamer 188, 0.1-1% Cola Lipid C and 0.1-10% sodium bicarbonate by weight. The remainder of the formulation consists of water.
- the formulation comprises 0.01% by weight polyhexamethylene biguanide (PMBH), 1% poloxamer 188, 0.25% Cola Lipid C and 0.5% sodium bicarbonate by weight. The remainder of the formulation consists of water.
- PMBH polyhexamethylene biguanide
- the remainder of the formulation consists of water.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a new formulation that has antiseptic and antibacterial properties and has the effect of breaking down the enzyme contained in the exudate formed in the wounds, to be used in the treatment of wounds.
Description
DESCRIPTION
NOVEL FORMULATION FOR USING IN THE TREATMENT OF WOUNDS
Technical Field
The invention relates to a new formulation that has antiseptic and antibacterial properties and has the effect of breaking down the enzyme contained in the exudate formed in the wounds, to be used in the treatment of wounds.
The State of Art
Topical applications used for the purpose of treating wounds are usually in the form of solutions or gels. In these products, formulations containing polynexamethylene biguanide (PHMB) and surfactant are commonly preferred.
The effectiveness of the existing products is to clean the layers on the wound surface and to provide wound antisepsis, especially in chronic wounds. On the wound surface, there are remnants of wound exudate, layers of discarded and thickened fibrin, layers of necrotic tissue and cell debris. These layers prepare a suitable environment for pathogenic microbes to infect the wound. Even in the absence of pathogenic microbes, removal of the layers on the wound surface and deep cleaning and disinfection of the wound are extremely important factors in accelerating the healing process.
In solutions used in the prior art for wound healing, PHMB is a suitable compound as a microbicide with good tissue tolerance. Wound compositions containing PHMB applied in the form of gels and lotions are known. However, in the compositions mentioned, situations arise such as not providing protection satisfactorily, not cleaning the wound from harmful substances, not reducing pain, not having an ingredient that will support the healing process, and not providing moisturizing.
W02015107183 Al relates to new formulations useful in the topical treatment of skin and oromucosal wounds. The formulations disclosed in the document consist of a polyhexamethylene biguanide as an antimicrobial agent, purified water and a triblock copolymer composed of a triblock copolymer, in particular polyethylene oxide and polypropylene oxide, and more particularly a poloxamer, and may be in solution or gel form. In the document, there is no explanation for the sodium bicarbonate content and function.
In the patent document with publication number EP1404311 Bl, a wound healing product formulated to be used in wound dressing is disclosed. The formulation contains polyhexanide, at least one surfactant
and hydroxyethyl cellulose. However, there is no cytotoxic antimicrobial active compound that increases wound collagen formation in the application. The absence of such an ingredient indirectly contributes to the healing process of the wound.
As a result, an improvement needs to be made since current applications cannot solve problems in the technical field.
The Purpose of the Invention
The invention aims to bring a solution for the negative aspects for new formulation for using in the treatment of wounds, stated above, constructed with the inspiration from the current state of art.
The invention is inspired by current situations and aims to solve the above-mentioned disadvantages.
The main purpose of the invention is to develop a new formulation for use in the treatment of wounds. This formulation, unlike the products in the state of the art, comprises sodium bicarbonate and accordingly, it is possible to break down the enzyme contained in the exudate formed in the wounds.
The structural and characteristic features and all advantages of the invention in the detailed description will be understood clearly, therefore the evaluation should be made by taking the detailed explanation into consideration.
Detailed Explanation of the Invention
In this section, the preferred embodiment of the invention is clarified such that there is no limiting effect for the sake of better understanding the subject.
The invention relates to a new formulation that has antiseptic and antibacterial properties and has the effect of breaking down the enzyme contained in the exudate formed in the wounds, to be used in the treatment of wounds. The formulation which is the subject of the invention comprises polyhexamethylene biguanide (PMBH) as an active ingredient (preservative). In addition, as surfactant, poloxamer and Cola Lipid C are also included in the formulation. Another ingredient in the formulation is sodium bicarbonate, which acts as an enzyme-dissolving aid. PHMB, poloxamer and Cola Lipid C provide antiseptic and antibacterial effects to the formulation. Unlike the state of the art, sodium bicarbonate in the formulation also breaks down the enzyme contained in the exudate and brings a new feature to the product.
In an embodiment of the invention, the formulation comprises 0.01-10% polyhexamethylene biguanide (PMBH), 0.01-10% poloxamer 188, 0.1-1% Cola Lipid C and 0.1-10% sodium bicarbonate by weight. The remainder of the formulation consists of water.
5 In one embodiment of the invention, the formulation comprises 0.01% by weight polyhexamethylene biguanide (PMBH), 1% poloxamer 188, 0.25% Cola Lipid C and 0.5% sodium bicarbonate by weight. The remainder of the formulation consists of water.
As an alternative to polyhexamethylene biguanide (PMBH), there are antiseptic products containing silver 0 ions, but the loss of the effect of silver in bacteria that have developed resistance to antibiotics makes Polyhexamethylene biguanide superior in this regard.
Claims
1. A formulation for use in the treatment of wounds, comprising
• polyhexamethylene biguanide (PMBH) and at least one surfactant. characterized by comprising
• sodium bicarbonate to break down the enzyme contained in the exudate formed in the wounds.
2. A formulation according to Claim 1, comprising Poloxamer 188 as surfactant.
3. A formulation according to Claim 1 , comprising Cola Lipid C as surfactant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2022/020068 | 2022-12-22 | ||
| TR2022020068 | 2022-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024136781A1 true WO2024136781A1 (en) | 2024-06-27 |
Family
ID=91589773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2023/050010 WO2024136781A1 (en) | 2022-12-22 | 2023-01-06 | Novel formulation for using in the treatment of wounds |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024136781A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3096727B1 (en) * | 2014-01-24 | 2018-03-14 | Avent, Inc. | Traumatic wound dressing system with conformal cover |
| US10888557B2 (en) * | 2015-04-23 | 2021-01-12 | Sydnexis, Inc. | Ophthalmic composition |
-
2023
- 2023-01-06 WO PCT/TR2023/050010 patent/WO2024136781A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3096727B1 (en) * | 2014-01-24 | 2018-03-14 | Avent, Inc. | Traumatic wound dressing system with conformal cover |
| US10888557B2 (en) * | 2015-04-23 | 2021-01-12 | Sydnexis, Inc. | Ophthalmic composition |
Non-Patent Citations (1)
| Title |
|---|
| MCLAIN NIAMH EM, MOORE ZENA EH, AVSAR PINAR: "Wound cleansing for treating venous leg ulcers", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 3, no. 3, 10 March 2021 (2021-03-10), US , pages 1 - 46, XP093188749, ISSN: 1465-1858, DOI: 10.1002/14651858.CD011675.pub2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2756848T3 (en) | Antimicrobial compositions and methods that employ them | |
| CN108135745B (en) | Efficient novel fast deposition film-forming compositions for wound treatment | |
| JP7118022B2 (en) | Use of seaprose to remove bacterial biofilms | |
| Kaye | Topical antibacterial agents | |
| US20220143077A1 (en) | Antimicrobial and cleansing composition | |
| Amtha et al. | Povidone-iodine in dental and oral health: a narrative review | |
| WO2024136781A1 (en) | Novel formulation for using in the treatment of wounds | |
| Khan | Honey compared with silver sulphadiazine as burn wound dressing | |
| WO2008041031A1 (en) | Wound healing compositions | |
| Kingsley et al. | Suprasorb® X+ PHMB: antimicrobial and hydrobalance action in a new wound dressing | |
| JP3054758B2 (en) | Trauma composition | |
| US20070010582A1 (en) | Use of N-chlorotaurine for treatment of oozing tissue deficiencies | |
| RU2682711C1 (en) | Antiseptic | |
| Smith | Successful management of infected wounds using a solution and gel containing Betaine and PHMB | |
| Sumner | Cleansing Solutions | |
| US20080207750A1 (en) | Use of N-Chlorotaurine for Treatment of Oozing Tissue Deficiencies | |
| Allorto | Importance of TIME in burn management and assessment | |
| CN118369090A (en) | Composition for acute and chronic wounds | |
| HAVE | The Problem-Biofilm | |
| TH84570B (en) | A new solution for wound healing and skin hygiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23907974 Country of ref document: EP Kind code of ref document: A1 |